Novo Nordisk lowers cost of Ozempic® to $499 per month for self-paying patients, in support of patient access to authentic, FDA-approved semaglutide medicines
— Offer supports access for eligible patients without insurance to FDA-approved Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg, the GLP-1 medicine with the broadest range of FDA-approved indications for adults with type 2 diabetes1 — For the first time, Ozempic® is available via home delivery through NovoCare® Pharmacy. Patients using traditional pharmacies […]